CPIX Fundamental Analysis - CUMBERLAND PHARMACEUTICALS

Fundamental Rating

Overall CPIX gets a fundamental rating of 4 out of 10. We evaluated CPIX against 196 industry peers in the Pharmaceuticals industry. While CPIX seems to be doing ok healthwise, there are quite some concerns on its profitability. CPIX is valued correctly, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CPIX had positive earnings in the past year.

In the past year CPIX had a positive cash flow from operations.

In the past 5 years CPIX always reported negative net income.

Of the past 5 years CPIX 4 years had a positive operating cash flow.

1.2 Ratios

With a decent Return On Assets value of -4.32%, CPIX is doing good in the industry, outperforming 71.43% of the companies in the same industry.

Looking at the Return On Equity, with a value of -10.47%, CPIX is in the better half of the industry, outperforming 74.49% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-4.32%
ROE	-10.47%
ROIC	N/A

ROA(3y)-7.42%

ROA(5y)-5.97%

ROE(3y)-21.64%

ROE(5y)-16.04%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CPIX has a Gross Margin of 83.99%. This is amongst the best in the industry. CPIX outperforms 89.80% of its industry peers.

CPIX's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for CPIX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	83.99%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.33%

GM growth 5Y1.04%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.

CPIX has less shares outstanding than it did 1 year ago.

CPIX has less shares outstanding than it did 5 years ago.

CPIX has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.86, we must say that CPIX is in the distress zone and has some risk of bankruptcy.

CPIX has a Altman-Z score of 0.86. This is comparable to the rest of the industry: CPIX outperforms 58.67% of its industry peers.

CPIX has a debt to FCF ratio of 0.75. This is a very positive value and a sign of high solvency as it would only need 0.75 years to pay back of all of its debts.

Looking at the Debt to FCF ratio, with a value of 0.75, CPIX belongs to the top of the industry, outperforming 95.41% of the companies in the same industry.

CPIX has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.

CPIX has a Debt to Equity ratio of 0.19. This is comparable to the rest of the industry: CPIX outperforms 47.45% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.19
Debt/FCF	0.75
Altman-Z	0.86

ROIC/WACCN/A

WACC9.35%

2.3 Liquidity

A Current Ratio of 1.30 indicates that CPIX should not have too much problems paying its short term obligations.

CPIX has a worse Current ratio (1.30) than 72.96% of its industry peers.

CPIX has a Quick Ratio of 1.17. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.17, CPIX is not doing good in the industry: 70.41% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.3
Quick Ratio	1.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 207.69% over the past year.

CPIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.34%.

The Revenue has been growing slightly by 1.95% on average over the past years.

EPS 1Y (TTM)207.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%100%

Revenue 1Y (TTM)11.34%

Revenue growth 3Y1.71%

Revenue growth 5Y1.95%

Sales Q2Q%10.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.57, CPIX is valued on the expensive side.

Compared to the rest of the industry, the Price/Earnings ratio of CPIX indicates a rather cheap valuation: CPIX is cheaper than 81.12% of the companies listed in the same industry.

CPIX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	24.57
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CPIX is valued cheaply inside the industry as 84.18% of the companies are valued more expensively.

93.37% of the companies in the same industry are more expensive than CPIX, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	7.41
EV/EBITDA	13.68

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CPIX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (9/19/2025, 10:55:57 AM)

3.44

+0.13 (+3.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-05 2025-08-05/amc

Earnings (Next)11-05 2025-11-05

Inst Owners28.76%

Inst Owner Change-13.97%

Ins Owners3.46%

Ins Owner Change0%

Market Cap51.46M

Analysts43.33

Price TargetN/A

Short Float %0.6%

Short Ratio0.83

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	24.57
Fwd PE	N/A
P/S	1.22
P/FCF	7.41
P/OCF	7.23
P/B	1.84
P/tB	4.64
EV/EBITDA	13.68

EPS(TTM)0.14

EY4.07%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.46

FCFY13.49%

OCF(TTM)0.48

OCFY13.84%

SpS2.81

BVpS1.87

TBVpS0.74

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.32%
ROE	-10.47%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	83.99%
FCFM	16.5%

ROA(3y)-7.42%

ROA(5y)-5.97%

ROE(3y)-21.64%

ROE(5y)-16.04%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.33%

GM growth 5Y1.04%

F-Score7

Asset Turnover0.62

Health

		Industry Rank	Sector Rank
Debt/Equity	0.19
Debt/FCF	0.75
Debt/EBITDA	1.85
Cap/Depr	3.11%
Cap/Sales	0.43%
Interest Coverage	N/A
Cash Conversion	251.96%
Profit Quality	N/A
Current Ratio	1.3
Quick Ratio	1.17
Altman-Z	0.86

F-Score7

WACC9.35%

ROIC/WACCN/A

Cap/Depr(3y)16.58%

Cap/Depr(5y)20.37%

Cap/Sales(3y)2.19%

Cap/Sales(5y)2.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)207.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%100%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)11.34%

Revenue growth 3Y1.71%

Revenue growth 5Y1.95%

Sales Q2Q%10.05%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y60.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-12.79%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-29.42%

OCF growth 3YN/A

OCF growth 5YN/A

CUMBERLAND PHARMACEUTICALS (CPIX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens